BANK OF MONTREAL /CAN/ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 94 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2022$2,104,000
+7.7%
205,680
-5.4%
0.00%0.0%
Q2 2022$1,953,000
+5480.0%
217,527
+13470.0%
0.00%
Q1 2021$35,000
-72.4%
1,603
-78.9%
0.00%
Q4 2020$127,000
+202.4%
7,583
+171.2%
0.00%
Q3 2020$42,000
-56.7%
2,796
-38.1%
0.00%
Q2 2020$97,000
+410.5%
4,514
+436.1%
0.00%
Q1 2020$19,000
-88.7%
842
-87.0%
0.00%
Q4 2019$168,000
+73.2%
6,496
+30.7%
0.00%
Q3 2019$97,000
-94.3%
4,969
-95.2%
0.00%
-100.0%
Q2 2019$1,696,000
+21100.0%
103,856
+28276.0%
0.00%
Q1 2019$8,000
-65.2%
366
-59.3%
0.00%
Q4 2018$23,000
+21.1%
899
+53.7%
0.00%
Q3 2018$19,000
+35.7%
585
-1.2%
0.00%
Q2 2018$14,000
-90.7%
592
-90.5%
0.00%
Q1 2018$151,000
+694.7%
6,210
+796.1%
0.00%
Q4 2017$19,000
-5.0%
693
+18.5%
0.00%
Q3 2017$20,000
-13.0%
5850.0%0.00%
Q2 2017$23,000
+4.5%
5850.0%0.00%
Q1 2017$22,000
+37.5%
5850.0%0.00%
Q4 2016$16,000
+60.0%
585
+120.8%
0.00%
Q3 2016$10,000
+150.0%
265
+47.2%
0.00%
Q2 2016$4,000
-33.3%
180
-42.5%
0.00%
Q1 2016$6,000
+20.0%
3130.0%0.00%
Q4 2015$5,000
+400.0%
313
+135.3%
0.00%
Q3 2015$1,000
-50.0%
1330.0%0.00%
Q2 2015$2,0000.0%1330.0%0.00%
Q1 2015$2,0000.0%1330.0%0.00%
Q4 2014$2,0001330.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2018
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 10,898,879$264,297,00023.51%
Foundation Asset Management, LP 399,537$9,689,0003.59%
Cormorant Asset Management, LP 1,300,000$31,525,0002.35%
Baupost Group 9,309,168$225,747,0002.18%
Old West Investment Management, LLC 109,320$2,651,0001.53%
SENZAR ASSET MANAGEMENT, LLC 187,856$4,555,0001.44%
Chescapmanager LLC 350,631$8,503,0001.27%
Virtus ETF Advisers LLC 32,989$800,0000.69%
Rock Springs Capital Management LP 652,600$15,826,0000.68%
NJ State Employees Deferred Compensation Plan 34,142$828,0000.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders